- Advertisement -

Crop Biotechnology: A Conversation With Dr. Jerry Feitelson – Forbes

It’s no secret that crop biotechnology (GM - genetically modified, GE - genetically edited,...the USDA biotech glossary is here) is a hot topic. Biotechnology...

Boston researcher Ramachandran selected to be inaugural dean of The University of Texas School of Public Health San Antonio

SAN ANTONIO — Vasan Ramachandran, MD, a distinguished public health researcher at Boston University and principal investigator of the Framingham Heart Study, has been named...

Global Biotechnology Reagents Market Size, Growth, Trends | Latest Industry Research Report, 2020-2025 | Covid-19 Impact Analysis – MENAFN.COM

(MENAFN - GetNews) According to report publish a new market research report on the 'Biotechnology Reagents Market: Global Size, Trends, Competitive, Historical and Forecast...

Sizing up microplastics: Nanofiltration uncovers environmental bioactivity

A new study reveals the bioactivity of microplastics in Lake Ontario using cutting-edge nanomembrane filtering technology. Researchers found all samples contained microplastics ranging between...

Hidden secrets written in stone

Decoding Hallett Cove with virtual reality Credit: University of South Australia It’s one of the best-known geological heritage...

Noise-Induced Hearing Loss Could Be Lessened by Restoring Zinc Signaling

Anyone who has been to a loud concert might know that feeling of ringing ears. And some people may experience temporary or permanent hearing...

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster...

ADC Developmentfrom Concept to Clinic

Read Now Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery...

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster...

ADC Developmentfrom Concept to Clinic

Read Now Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery...

Designing the Ecosystem for CGT Success

Read Now Preserving the Promise: Insights from The Cell Summit ’26 In July 2026, BioLife Solutions welcomed leaders from across the cell...

more new items

Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have revolutionized the treatment of type 2 diabetes (T2D). None of these blockbuster...

ADC Developmentfrom Concept to Clinic

Read Now Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the therapeutic activity of small molecule payloads, enabling targeted delivery...

Designing the Ecosystem for CGT Success

Read Now Preserving the Promise: Insights from The Cell Summit ’26 In July 2026, BioLife Solutions welcomed leaders from across the cell...